(firstQuint)Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration.

 This is an open-label, prospective, randomized study of intravitreally administered ranibizumab 0.

5 mg in subjects with unilateral neovascular AMD in which the fellow (study) eye is at high-risk for also developing conversion to neovascular AMD.

 The Study will determine the efficacy of a quarterly injection of Ranibizumab to prevent the conversion of dry age-related macular degeneration to neovascular AMD in high risk eyes.

.

 Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration@highlight

To evaluate Ranibizumab as prophylaxis against the conversion to neovascular Age-Related Macular Degeneration